🔎 Trials Near Me

ホーム › 骨髄異形成症候群 › ミズーリ州

ミズーリ州における骨髄異形成症候群の臨床試験

ミズーリ州内の拠点で、骨髄異形成症候群に関する15件の研究が参加者を募集しています。

ミズーリ州内の都市

公式研究テキスト(英語)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  • Parkland Health Center - Farmington, Farmington
  • Sainte Genevieve County Memorial Hospital, Sainte Genevieve
  • Missouri Baptist Medical Center, St Louis
  • 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06577441

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • Washington University School of Medicine, St Louis
  • 他2件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06484062

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • Parkland Health Center - Farmington, Farmington
  • 他10件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • Washington University St.Louis, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  • American Oncology Partners P.A. MidAmerica Cancer Care, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07422480

Collection of Tissue Samples for Cancer Research

  • Washington University - St. Louis, St Louis
被験者募集中観察研究
2 Months · 全性別 · 2026/09/16更新 · NCT00900198

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Missouri Children's Hospital, Columbia
  • Children's Mercy Hospitals and Clinics, Kansas City
  • Cardinal Glennon Children's Medical Center, St Louis
  • 他2件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  • MidAmerica Cancer Care, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06499285

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

  • WashU Medicine, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/10更新 · NCT05308264

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

  • Washington University School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/23更新 · NCT05483010

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

  • Washington University School of Medicine, St Louis
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/03/23更新 · NCT04742634

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

  • Washington University School of Medicine, St Louis
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2025/12/11更新 · NCT05434598

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Kansas City
  • Massive Bio SYNERGY-AI site, St Louis
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

  • Washington University School of Medicine, St Louis
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2025/10/16更新 · NCT04986657

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。